Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries
"Jorge Mestre-Ferrandiz Jorge Mestre-Ferrandiz. Director of Consultancy. Office of Health Economics. London."
Yes, I believe we can incentivise the development and use of orphan drugs at the same time. Since the advent of specific legislation on orphan drugs (1983 in the US, 1993 in Japan, 1997 in Australia and 2000 in the EU), there has been a political debate on whether additional incentives, implemented as a result of such legislation, are appropriate. We have seen something similar before with the "neglected diseases", diseases that particularly afflict the world's poorest populations.